<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="91658" href="/d/html/91658.html" rel="external">see "Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Drug information"</a> and <a class="drug drug_patient" data-topicid="91895" href="/d/html/91895.html" rel="external">see "Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F47022752"><span class="drugH1">Brand Names: US</span>
<ul>
<li>SMOFlipid</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871675"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>SMOFlipid</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F22874952"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Caloric Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462685"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f7203a-e10c-47ac-b028-3c148b2d3e81">Parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The amount of lipid injectable emulsion needed to prevent essential fatty acid deficiency (EFAD) varies based on age and lipid product; the amount of lipid injectable emulsion (fish oil and plant based) required to prevent EFAD will be higher than the doses of plant-based lipid injectable emulsion (eg, Intralipid); use of restrictive dosing protocol with lipid injectable emulsion (fish oil and plant based) may put patients at risk for EFAD (Carey 2019; ESPGHAN [Lapillonne 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: IV: Initial: 0.5 to 1 g/kg/day; increase by 0.5 to 1 g/kg/day to a maximum daily dose of 3 g/kg/<b>day</b> (Deshpande 2020; manufacturer's labeling). Studies have evaluated use of lipid injectable emulsion (fish oil and plant based) in neonates with GA range of 23 to 41 weeks and birthweights of 390 to 4,400 g and have shown use is safe and well tolerated (Casson 2020; Rayyan 2012; Repa 2018; Savini 2013; Skouroliakou 2012; Stramara 2020; Tomsits 2010).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812621"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f7203a-e10c-47ac-b028-3c148b2d3e81">Parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The amount of lipid injectable emulsion needed to prevent essential fatty acid deficiency (EFAD) varies based on age and lipid product; the amount of lipid injectable emulsion (fish oil and plant based) required to prevent EFAD will be higher than the doses of plant-based lipid injectable emulsion (eg, Intralipid); use of restrictive dosing protocol with lipid injectable emulsion (fish oil and plant based) may put patients at risk for EFAD (Carey 2019; ESPGHAN [Lapillonne 2018]). For patients receiving other lipid emulsion–based medications (eg, propofol), take the lipid content provided from these medications into consideration and reduce dosage as needed to avoid adverse effects such as fat overload syndrome (ASPEN [Mirtallo 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: IV: Initial: 0.5 to 1 g/kg/day; increase by 0.5 to 1 g/kg/day to a maximum daily dose of 3 g/kg/<b>day</b>; generally, lipids should account for ~25% to 50% of nonprotein calories (ESPGHAN [Lapillonne 2018]; Goulet 2020; Martindale 2020; Wassef 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;12 years: IV: Initial: 1 to 2 g/kg/day; increase by 0.5 to 1 g/kg/day to a maximum daily dose of 3 g/kg/<b>day</b>; generally, lipids should account for ~25% to 50% of nonprotein calories (ESPGHAN [Lapillonne 2018]; Goulet 2020; Martindale 2020; Wassef 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: Initial: 1 g/kg/day; maximum daily dose: 2.5 g/kg/<b>day</b> (manufacturer's labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729723"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F52729724"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Monitor liver function closely.</p></div>
<div class="block doa drugH1Div" id="F22781932"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="91658" href="/d/html/91658.html" rel="external">see "Lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF]): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For patients receiving other lipid emulsion-based medications (eg, propofol, clevidipine), reduce dosage to avoid fat overload syndrome (ASPEN [Mirtallo 2020]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3daa198-e6a0-4aec-9171-021d23fe6322">Energy/calories</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Energy/calories:</b>
<b>IV:</b> 1 to 2 g/kg/day (ASPEN [Mirtallo 2020]); daily dose may be infused over 12 to 24 hours; maximum daily dose: 2.5 g/kg/day. <b>Note:</b> Lipid injectable emulsion (ILE) should provide 15% to 30% of energy (ASPEN [Mirtallo 2020]) and not exceed 60% of the total daily energy requirements. At the onset of therapy, observe patient for any immediate allergic reactions (eg, dyspnea, cyanosis, fever, pruritus [ASPEN (Mirtallo 2020)]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for increased serum triglycerides:</b> If triglycerides &gt;400 mg/dL, lower dose/infusion rate or stop infusion and advance in smaller increments once triglycerides are &lt;400 mg/dL. Use is contraindicated with triglycerides &gt;1,000 mg/dL (ASPEN [Mirtallo 2020]; Siparsky 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990488"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987773"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F22801480"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in neonates, infants, children, and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Anemia (neonates, infants, children: 18%; adults: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (≤3%), tachycardia (≤2%), thrombophlebitis (adults: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (adults: ≤1%), skin rash (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (2% to 5%), hypertriglyceridemia (neonates, infants, children: ≤1%), hypervolemia (neonates, infants, children: ≤1%), increased gamma-glutamyl transferase (neonates, infants, children: 6%; adults: ≤1%), metabolic acidosis (neonates, infants, children: ≤1%), nutrition disorder (essential fatty acid deficiency: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2% to 4%), cholestasis (≤4%), diarrhea (≤2%), dysgeusia (adults: ≤1%), dyspepsia (adults: 2%), flatulence (adults: 4%), nausea (adults: 9%), vomiting (7% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased (neonates, infants, children: 4%; adults: ≤1%), leukocytosis (adults: ≤1%), thrombocytopenia (neonates, infants, children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (≤1%; including increased alanine aminotransferase), hyperbilirubinemia (neonates, infants, children: 3%), increased serum alkaline phosphatase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including nosocomial infection; neonates, infants, children: ≤6%), sepsis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adults: ≤1%), headache (adults: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (adults: ≤1%), pneumonia (adults: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, palpitations, phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, malaise</p></div>
<div class="block coi drugH1Div" id="F22781923"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fish, egg, soybean, or any other component of the formulation; severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations &gt;1,000 mg/dL). <b>Note:</b> Although the manufacturer's labeling lists hypersensitivity to peanut as a contraindication, the product does not contain peanut; however, a low risk of cross-reactivity between soy and peanuts may exist.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hepatic insufficiency; severe blood coagulation disorders; severe renal insufficiency without access to hemofiltration or dialysis; acute shock; acute pulmonary edema; hyperhydration; decompensated cardiac insufficiency; unstable conditions (eg, severe post-traumatic conditions, uncompensated diabetes mellitus, acute MI, CVA, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration).</p></div>
<div class="block war drugH1Div" id="F22781924"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fat overload syndrome: Although rare, a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance resulting in a sudden deterioration in the patient's condition accompanied by fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and CNS (eg, coma) may occur; usually reversible upon discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Although the exact etiology is unknown and likely multifactorial, parenteral nutrition associated liver disease (PNALD) has been reported in patients receiving parenteral nutrition for extended periods of time and can present as cholestasis or steatohepatitis, fibrosis and cirrhosis, possibly leading to hepatic failure; cholecystitis and cholelithiasis have also been observed. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Contains soybean oil, fish oil, and egg phospholipids; hypersensitivity reactions may occur. Cross sensitivity has been observed between soybean and peanut. Discontinue use immediately if a reaction occurs and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertriglyceridemia: Impaired lipid metabolism with hypertriglyceridemia may occur in conditions such as inherited lipid disorders, obesity, diabetes mellitus, and metabolic syndrome. In adults with triglycerides &gt;400 mg/dL, reduce dose/infusion rate or stop infusion and monitor triglycerides. In pediatric patients, lower triglyceride levels may be associated with adverse reactions. Assess high-risk patients for their overall energy intake, including other lipid or dextrose sources and medications that may affect lipid and dextrose metabolism, to minimize risk of new or worsening hypertriglyceridemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Catheter-related bloodstream infections may occur due to lipid emulsions supporting microbial growth; ensure aseptic techniques are used for catheter placement, maintenance, preparation, and administration and frequently assess catheter for signs of infection (eg, discharge, edema, redness).</p>
<p style="text-indent:-2em;margin-left:4em;">• Refeeding syndrome: Refeeding severely undernourished patients with parenteral nutrition may result in the refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: The use of fat emulsion has been associated with anemia likely due to hemodilution (Zellner 1967). Use with caution in patients with anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fat embolism: Use with caution in patients who may be at danger for fat embolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may contain aluminum, which may accumulate following prolonged administration in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Energy expenditure and requirements may be lower in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Acute respiratory distress, metabolic acidosis, hypertriglyceridemia, and death have been reported in neonates and infants after rapid infusion. Do not exceed recommended daily doses or hourly infusion rates. Preterm infants and low birth weight infants have poor clearance of IV lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: May contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: The too-rapid administration of lipid emulsion can cause fluid and/or fat overloading, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, pulmonary edema, impaired pulmonary diffusion capacity, or metabolic acidosis; hourly infusion rate should be as low as possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Simultaneous infusion of a carbohydrate/amino acid solution is recommended to minimize the risk of metabolic acidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory tests: Lipids in the bloodstream may interfere with some laboratory tests (eg, hemoglobin, lactate dehydrogenase, bilirubin, oxygen saturation). Conduct these tests ≥6 hours after stopping the infusion. Products contain vitamin K, which may counteract anticoagulant activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56302018"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Although moderate to severe essential fatty acid deficiency (EFAD) was not seen in short-term (eg, ≤28 days) pediatric clinical trials of lipid injectable emulsion (fish oil and plant based) (eg, Smoflipid), cases of EFAD have been reported in pediatric and adult patients in the postmarketing period, usually occurring after more than 28 days of therapy. Due to the differences in compositions of the available lipid injectable emulsions, the amount of lipid injectable emulsion to prevent EFAD will vary by product; the amount of lipid injectable emulsion (fish oil and plant based) (eg, Smoflipid) required to prevent EFAD will be higher than the doses of plant-based lipid injectable emulsion (eg, Intralipid); use of restrictive dosing protocols with lipid injectable emulsion (fish oil and plant based) may put patients at risk for EFAD (Carey 2019; ESPGHAN [Lapillonne 2018]). Patients should be monitored for signs and symptoms of EFAD (eg, abnormal fatty acid levels, skin manifestations, poor growth); pediatric patients are vulnerable to neurologic complications if adequate amounts of essential fatty acids are not provided.</p>
<p style="text-indent:0em;margin-top:2em;">Development of parenteral nutrition–associated liver disease (PNALD), also known as intestinal failure–associated liver disease, has been associated with IV administration of phytosterols contained in plant-based lipid injectable emulsions, including Smoflipid. In a randomized trial (n=161), parenteral nutrition–associated cholestasis (PNAC), a precursor to PNALD, developed less frequently in neonates and infants receiving Smoflipid as part of parenteral nutrition compared to those receiving solely plant-based lipid injectable emulsion (2.4% vs 11.5%); PNAC usually occurred with &gt;28 days of therapy. Closely monitor for PNAC/PNALD; if abnormalities occur consider dose reduction or discontinuation.</p>
<p style="text-indent:0em;margin-top:2em;">Hypertriglyceridemia may occur in patients receiving lipid injectable emulsions. Pediatric patients with serum triglyceride concentrations &gt;200 mg/dL are considered to have hypertriglyceridemia. Hypertriglyceridemia is associated with excess carbohydrate or fat intake, poor glycemic control, and carnitine deficiency. Assess overall energy intake in high-risk patients, including other lipid or dextrose sources and medications that may affect lipid and dextrose metabolism to minimize risk of new or worsening hypertriglyceridemia. Monitor serum triglyceride levels to avoid potential complications of hypertriglyceridemia such as pancreatitis, lipid pneumonitis, and neurologic changes, including kernicterus (ASPEN [Cober 2021]; manufacturer's labeling).</p>
<p style="text-indent:0em;margin-top:2em;">Rapid infusion has been associated with fat overload syndrome in pediatric patients. In a case report, a 2 year old inadvertently received 20 grams (1.75 g/kg) of lipid injectable emulsion (fish oil and plant based) over 30 minutes. The patient developed vomiting, dyspnea, tachypnea, pallor, tachycardia, hypertension, and metabolic acidosis, which was determined to be fat overload syndrome. Treatment included fluids, platelets, albumin, fresh frozen plasma, RBC infusions, and filgrastim; laboratory results slowly returned to normal over a week (Hojsak 2014).</p></div>
<div class="block foc drugH1Div" id="F47022753"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SMOFlipid: 20% (100 mL, 250 mL, 500 mL, 1000 mL) [contains egg phospholipids (egg lecithin)]</p></div>
<div class="block geq drugH1Div" id="F47022751"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F48851915"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (SMOFlipid Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20% (per mL): $0.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871676"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SMOFlipid: 20% (100 mL, 250 mL, 500 mL) [contains egg phospholipids (egg lecithin)]</p></div>
<div class="block adip drugH1Div" id="F53570495"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Smoflipid contains 0.163 to 0.225 mg/mL of all-rac-α-tocopherol; take into consideration the amount of α-tocopherol provided by Smoflipid when determining the need for additional supplementation.</p></div>
<div class="block admp drugH1Div" id="F52614548"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Prior to opening the overwrap, the integrity indicator should be inspected. If the indicator is black, the overwrap is damaged; do not use. Gently invert bag prior to use. Do not use if discolored or if the emulsion contains a precipitate, phase separation, or there are leaks in the bag.</p>
<p style="text-indent:-2em;margin-left:2em;">Experts recommend parenteral nutrition admixtures and lipid emulsions for neonates and infants be protected from light as soon as possible after preparation and through infusion (ASPEN [Robinson 2021]). May be used as part of a parenteral nutrition admixture (3-in-1) or infused simultaneously with amino acid and dextrose mixtures by means of Y-connector located near infusion site (flow rates of each solution should be controlled separately by infusion pumps). All lipid emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2-micron in-line filter only (ASPEN [Cober 2021]; ASPEN [Worthington 2021]; ISMP 2016). Administration may occur via peripheral line or central venous infusion using di-2-ehtylhexyl phthalate (DEHP)-free administration sets and lines. Infusion sets that contain DEHP, including infusion sets that contain PVC, should not be used. When administered with dextrose and amino acids, the choice of a central or peripheral infusion depends on the osmolarity of the final infusate (osmolarity ≥900 mOsm/L must be infused through a central vein). To prevent air embolism, use a nonvented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible bags in series, fully evacuate residual gas in the bag prior to administration, do not pressurize the flexible bag to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the bag runs dry. Change tubing after each infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, and Children &lt;2 years: IV: Initiate at 0.1 to 0.2 <b>mL</b>/kg/<b>hour</b> for 15 to 30 minutes; if no untoward effects occur after 30 minutes, the infusion rate may be gradually increased to 0.75 <b>mL</b>/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents ≤17 years: IV: Initiate at 0.2 to 0.4 <b>mL</b>/kg/<b>hour</b> for 15 to 30 minutes; if no untoward effects occur after 30 minutes, the infusion rate may be gradually increased to 0.75 <b>mL</b>/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;17 years: IV: Initiate at 0.2 <b>mL</b>/kg/<b>hour</b> for 15 to 30 minutes; if no untoward effects occur after 30 minutes, the infusion rate may be gradually increased to 0.5 <b>mL</b>/kg/<b>hour</b>.</p></div>
<div class="block adm drugH1Div" id="F22781948"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV: </b>Administer by IV infusion through a 1.2-micron in-line filter via peripheral line or central venous infusion using DEHP-free administration sets and lines. Initial rate of infusion should be 0.2 mL/kg/hour for the first 15 to 30 minutes; gradually increase until reaching the required rate after 30 minutes as tolerated. Do not exceed a rate of 0.5 mL/kg/hour. May be simultaneously infused with amino acid and dextrose mixtures by means of Y-connector located near infusion site (flow rates of each solution should be controlled separately by infusion pumps) and infused through a 1.2-micron in-line filter (Worthington 2021). When administered with dextrose and amino acids, the choice of a central or peripheral infusion depends on the osmolarity of the final infusate (osmolarity ≥900 mOsm/L must be infused through a central vein). All lipid emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2-micron in-line filter only (ISMP 2016; Worthington 2021). To prevent air embolism, use a nonvented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible bags in series, fully evacuate residual gas in the bag prior to administration, do not pressurize the flexible bag to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the bag runs dry.</p></div>
<div class="block sts drugH1Div" id="F22781926"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at ≤25°C (≤77°F). Store in overpouch until ready for use; once removed from overpouch, use immediately. If not used immediately, the manufacturer suggests storing at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours; after removal from refrigeration, the emulsion should be infused within 12 hours when using a Y-connector or within 24 hours when used as part of an admixture. Do not freeze. Avoid excessive heat. Protect admixed solutions from light.</p></div>
<div class="block usep drugH1Div" id="F53571110"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Source of calories and essential fatty acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated (FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F55852551"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:0em;display:inline">Lipid injectable emulsion may be confused with intravenous iron if abbreviated. If abbreviated, use intravenous lipid emulsion (ILE) to avoid confusion (ASPEN 2018; ASPEN [Mirtallo 2020]).</p></div>
<div class="block cyt drugH1Div" id="F47086803"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F47086800"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Lipid Emulsion (Fish Oil and Plant Based) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F22781938"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Caloric content: 2 kcal/mL</p>
<p style="text-indent:-2em;margin-left:2em;">Phosphorus: 15 mmol/L</p>
<p style="text-indent:-2em;margin-left:2em;">Lipid emulsion should not exceed 60% of the total daily calories.</p></div>
<div class="block pri drugH1Div" id="F22781921"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Severe maternal malnutrition may cause adverse events to the fetus/neonate. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines 2002).</p></div>
<div class="block mopp drugH1Div" id="F53571111"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of infection (including vascular access device complications), fluid and electrolyte status, serum osmolarity, blood glucose, blood counts (including platelets and coagulation parameters), signs and symptoms of pleural or pericardial effusion, fat overload syndrome, refeeding syndrome, and/or hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor renal function tests periodically. Monitor triglycerides before initiation of lipid injectable emulsion therapy, and at least weekly during hospitalization and after changes are made in the amount of lipid injectable emulsion administered; once stable, monitoring frequency may range from weekly to monthly depending on patient clinical status and history; monitor more frequently in patients at risk for hypertriglyceridemia such as premature infants (especially those that are extremely low birthweight); patients receiving high lipid injectable emulsion or glucose doses; critically ill patients; patients with sepsis, severe thrombocytopenia, or coagulopathy; patients with pancreatitis or hepatic disease; or in patients receiving other lipid emulsion–based medications (eg, propofol) (ASPEN [Cober 2021]; ASPEN [Mirtallo 2020]; ESPGHAN [Lapillonne 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor hepatic function (direct bilirubin, ALT/AST, alkaline phosphatase, and gamma-glutamyl transferase) at least weekly during hospitalization and at least every 3 months for patients receiving home parenteral nutrition (Deshpande 2020; ESPGHAN [Lapillonne 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of essential fatty acid deficiency (EFAD) (eg, alopecia, eczematous dermatitis, poor wound healing, growth retardation). Evaluate essential fatty acid concentrations in malnourished patients, patients exhibiting signs and symptoms of EFAD, patients receiving less than the recommended dose of lipid emulsion, or patients who have received lipid emulsion (fish oil and plant based) for ≥1 month; more frequent monitoring may be warranted in malnourished patients (ASPEN [Cober 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for fat overload, particularly if lipid emulsion dose is &gt;3 g/kg/day, infusion rate exceeds the maximum recommended rate, or inadvertent rapid infusion of lipid emulsion occurs (ASPEN [Cober 2021]).</p></div>
<div class="block pha drugH1Div" id="F22781927"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lipid emulsion is metabolized and utilized as an energy source; provides fatty acids (linoleic acid, oleic acid, caprylic acid, palmitic acid, capric acid, stearic acid, and alpha linolenic acid) and omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) necessary for normal structure and function of cell membranes.</p></div>
<div class="block phk drugH1Div" id="F22781929"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Fatty acids, phospholipids, and glycerol are metabolized by cells to adenosine triphosphate (ATP), carbon dioxide, and water</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Biliary (phospholipids)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50168918"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Multi oil Fat Emulsion (C6-24)</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">SMOFlipid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Smoflipid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Society for Parenteral and Enteral Nutrition (ASPEN). Definition of terms, style, and conventions used in ASPEN board of directors–approved documents. http://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/ASPEN%20Definition%20of%20Terms,%20Style,%20and%20Conventions%20Used%20in%20ASPEN%20Board%20of%20Directors%E2%80%93Approved%20Documents.pdf. Published May 2018. Accessed May 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11841046">
<a name="11841046"></a>ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. <i>JPEN J Parenter Enteral Nutr</i>. 2002;26(1 Suppl):1-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/11841046/pubmed" id="11841046" target="_blank">11841046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27528126">
<a name="27528126"></a>Biesboer AN, Stoehr NA. A product review of alternative oil-based intravenous fat emulsions. <i>Nutr Clin Pract</i>. 2016;31(5):610-618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/27528126/pubmed" id="27528126" target="_blank">27528126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29846008">
<a name="29846008"></a>Carey AN, Rudie C, Mitchell PD, Raphael BP, Gura KM, Puder M. Essential fatty acid status in surgical infants receiving parenteral nutrition with a composite lipid emulsion: a case series. <i>JPEN J Parenter Enteral Nutr</i>. 2019;43(2):305-310. doi:10.1002/jpen.1311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/29846008/pubmed" id="29846008" target="_blank">29846008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31672409">
<a name="31672409"></a>Casson C, Nguyen V, Nayak P, et al. A comparison of Smoflipid® and Intralipid® in the early management of infants with intestinal failure. <i>J Pediatr Surg</i>. 2020;55(1):153-157. doi:10.1016/j.jpedsurg.2019.09.073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/31672409/pubmed" id="31672409" target="_blank">31672409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34705289">
<a name="34705289"></a>Cober MP, Gura KM, Mirtallo JM, et al. ASPEN lipid injectable emulsion safety recommendations part 2: Neonate and pediatric considerations. <i>Nutr Clin Pract</i>. 2021;36(6):1106-1125. doi:10.1002/ncp.10778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/34705289/pubmed" id="34705289" target="_blank">34705289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049399">
<a name="32049399"></a>Deshpande GC, Cai W. Use of lipids in neonates requiring parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2020;44(Suppl 1:S45-S54). doi:10.1002/jpen.1759<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/32049399/pubmed" id="32049399" target="_blank">32049399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049395">
<a name="32049395"></a>Goulet OJ, Cai W, Seo JM. Lipid emulsion use in pediatric patients requiring long-term parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2020;44(Suppl 1:S55-S67). doi:10.1002/jpen.1762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/32049395/pubmed" id="32049395" target="_blank">32049395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16870807">
<a name="16870807"></a>Hamilton C, Austin T, Seidner DL. Essential fatty acid deficiency in human adults during parenteral nutrition. <i>Nutr Clin Pract</i>. 2006;21(4):387-394. doi:10.1177/0115426506021004387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/16870807/pubmed" id="16870807" target="_blank">16870807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23520135">
<a name="23520135"></a>Hojsak I, Kolaček S. Fat overload syndrome after the rapid infusion of SMOFlipid emulsion. <i>JPEN J Parenter Enteral Nutr</i>. 2014;38(1):119-121. doi:10.1177/0148607113482001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/23520135/pubmed" id="23520135" target="_blank">23520135</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute for Safe Medication Practice (ISMP). IV fat emulsion needs a filter. <i>ISMP Medication Safety Alert</i>. January 14, 2016.</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>. Washington, DC: The National Academies Press, 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30143306">
<a name="30143306"></a>Lapillonne A, Fidler Mis N, Goulet O, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. <i>Clin Nutr</i>. 2018;37(6 Pt B):2324-2336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/30143306/pubmed" id="30143306" target="_blank">30143306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049392">
<a name="32049392"></a>Martindale RG, Berlana D, Boullata JI, et al. Summary of proceedings and expert consensus statements from the International Summit "Lipids in Parenteral Nutrition". <i>JPEN J Parenter Enteral Nutr</i>. 2020;44 Suppl 1:S7-S20. doi:10.1002/jpen.1746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/32049392/pubmed" id="32049392" target="_blank">32049392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32460429">
<a name="32460429"></a>Mirtallo JM, Ayers P, Boullata J, et al. ASPEN lipid injectable emulsion safety recommendations, part 1: background and adult considerations. <i>Nutr Clin Pract</i>. 2020;35(5):769-782. doi:10.1002/ncp.10496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/32460429/pubmed" id="32460429" target="_blank">32460429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22237883">
<a name="22237883"></a>Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. <i>JPEN J Parenter Enteral Nutr</i>. 2012;36(1 Suppl):81S-94S. doi:10.1177/0148607111424411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/22237883/pubmed" id="22237883" target="_blank">22237883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29269199">
<a name="29269199"></a>Repa A, Binder C, Thanhaeuser M, et al. A mixed lipid emulsion for prevention of parenteral nutrition associated cholestasis in extremely low birth weight infants: a randomized clinical trial. <i>J Pediatr</i>. 2018;194:87-93.e1. doi:10.1016/j.jpeds.2017.11.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/29269199/pubmed" id="29269199" target="_blank">29269199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34472142">
<a name="34472142"></a>Robinson DT, Ayers P, Fleming B, et al. Recommendations for photoprotection of parenteral nutrition for premature infants: An ASPEN position paper. <i>Nutr Clin Pract</i>. 2021;36(5):927-941. doi:10.1002/ncp.10747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/34472142/pubmed" id="34472142" target="_blank">34472142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23761482">
<a name="23761482"></a>Savini S, D'Ascenzo R, Biagetti C, et al. The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial. <i>Am J Clin Nutr</i>. 2013;98(2):312-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/23761482/pubmed" id="23761482" target="_blank">23761482</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Siparsky N. Postoperative parenteral nutrition. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22878361">
<a name="22878361"></a>Skouroliakou M, Konstantinou D, Agakidis C, et al. Cholestasis, bronchopulmonary dysplasia, and lipid profile in preterm infants receiving MCT/ω-3-PUFA-containing or soybean-based lipid emulsions. <i>Nutr Clin Pract</i>. 2012;27(6):817-824.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/22878361/pubmed" id="22878361" target="_blank">22878361</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Smoflipid (fat emulsion [fish oil based]) [product information]. Mount Kuring-gai NSW, Australia: Fresenius Kabi Australia Pty Limited; July 2020.</div>
</li>
<li>
<div class="reference">
                  SMOFlipid (lipid injectable emulsion) [prescribing information]. Uppsala, Sweden; Fresenius Kabi; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smoflipid.2">
<a name="Smoflipid.2"></a>SMOFlipid (lipid injectable emulsion) [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32027047">
<a name="32027047"></a>Stramara L, Hernandez L, Bloom BT, Durham C. Development of parenteral nutrition-associated liver disease and other adverse effects in neonates receiving SMOFlipid or Intralipid. <i>JPEN J Parenter Enteral Nutr</i>. 2020;44(8):1530-1534. doi:10.1002/jpen.1774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/32027047/pubmed" id="32027047" target="_blank">32027047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20531018">
<a name="20531018"></a>Tomsits E, Pataki M, Tölgyesi A, Fekete G, Rischak K, Szollár L. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2010;51(4):514-521. doi:10.1097/MPG.0b013e3181de210c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/20531018/pubmed" id="20531018" target="_blank">20531018</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration. Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34618376">
<a name="34618376"></a>Wassef J, Lipkin E, Hardigan P, Duro D. Trends in liver profile and nutrition outcomes in children undergoing intestinal rehabilitation using a mixed lipid injectable emulsion. <i>Nutr Clin Pract</i>. Published online October 7, 2021. doi:10.1002/ncp.10782<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/34618376/pubmed" id="34618376" target="_blank">34618376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30970011">
<a name="30970011"></a>Watrobska-Swietlikowska D. Stability of commercial parenteral lipid emulsions repacking to polypropylene syringes. <i>PLoS One</i>. 2019;14(4):e0214451. doi:10.1371/journal.pone.0214451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/30970011/pubmed" id="30970011" target="_blank">30970011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091206">
<a name="33091206"></a>Worthington P, Gura KM, Kraft MD, Nishikawa R, Guenter P, Sacks GS; ASPEN PN Safety Committee. Update on the use of filters for parenteral nutrition: an ASPEN position paper. <i>Nutr Clin Pract</i>. 2021;36(1):29-39. doi:10.1002/ncp.10587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/33091206/pubmed" id="33091206" target="_blank">33091206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6036266">
<a name="6036266"></a>Zellner DC, Iacono JM. "Dilution anemia" associated with multiple infusions of a fat emulsion. <i>Am J Clin Nutr</i>. 1967;20(7):766-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lipid-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smof-pediatric-drug-information/abstract-text/6036266/pubmed" id="6036266" target="_blank">6036266</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 110860 Version 75.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
